Android app on Google Play

ISIS Pharmaceuticals (ISIS) PT Raised to $46 at Needham & Company on Positive Data

September 23, 2013 2:13 PM EDT Send to a Friend
Get Alerts ISIS Hot Sheet
Price: $40.71 -3.71%

Rating Summary:
    6 Buy, 6 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 25 | New: 14
Trade ISIS Now!
Join SI Premium – FREE
Needham & Company Chad Messer reiterated a Buy rating and raised his price target on ISIS Pharmaceuticals (NASDAQ: ISIS) from $36 to $46 saying FCS may provide a faster path to market for ISIS-APOCIIIRx.

"Over the weekend ISIS released unexpected data from a Phase II study of ISIS-APOCIIIRx in familial chylomicronemia syndrome (FCS)," Messer notes. "While there were only 3 patients in the study, ISIS-APOCIIIRx achieved an unprecedented 69% reduction in triglycerides in this extremely hard to treat population. FCS is an ultra-orphan indication and may represent an even faster way to market for ISIS-APOCIIIRx which has shown impressive efficacy and excellent tolerability in multiple studies."

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $36.06 yesterday.




You May Also Be Interested In


Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Needham & Company

Add Your Comment